biomarker for the diagnosis of pleural effusion

Complement component as an emerging biomarker for the diagnosis of tuberculous pleural effusion

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100052990

Enrollment

Unknown

Registered

2021-11-07

Start date

2021-02-01

Completion date

Unknown

Last updated

2022-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberculous pleural effusion

Interventions

Gold Standard:TPE was diagnosed if Ziehl–Neelsen staining or Mtb culture of PF or pleural biopsy specimens were positive, or if a granuloma was present in the pleural biopsy specimens. MPE was diagnos

Index test:Complement&#32

component&#32

C1q,ELISA

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Identify patients with pleural effusion.

Exclusion criteria

Exclusion criteria: 1. Those who have received anti-tumor or anti-tuberculosis treatment within 5 years of sampling; 2. Patients with diabetes and immune deficiency diseases.

Design outcomes

Primary

Measure	Time frame
Complement component C1q;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactShi Huanzhong

Beijing Chao-Yang Hospital, Capital Medical University

shihuanzhong@ccmu.edu.cn+86 10 85231412

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026